Table 1 Type of trial and reporting of ethnic group profile data

Armstrong et al. [19]

17 (3) USA, Canada, and UK

Phase II

RCT everolimus v sunitinib [19]

Patients with metastatic non-clear-cell renal cell carcinoma

108; White 94 (87)

Non-white, 12 (11)

Black 12 (11)

Yao et al. [20]

97 (25) Europe, Japan, South Korea

Phase III

RCT everolimus v placebo

Patients with advanced progressive well-differentiated non-functional neuroendocrine tumours of the lung or gastrointestinal origin

302; White 230 (76)

50 (17)

Asian 50 (17)

Others 22 (7)

Schöffski et al., primary paper [21]^a)

Hudgens et al., quality of life paper [22]^b)

110 (22) USA, Latin America, Europe, Asia, Australasia

Phase III

RCT eribulin v dacarbazine [21]

Previously treated patients with advanced liposarcoma or leiomyosarcoma

452^a); White 330 (73)^a)

442^b)

White 322 (73)

Missing 63 (14)

46 (10)

Black/African-American 12 (3), Asian 34 (8), others or NA 76 (17)^a)

Black/African-American 12 (3)^b)

Japanese 1 (< 1)

Chinese 3 (< 1)

Other Asian 30 (7)

Native Hawaiian or other Pacific Islander 1 (< 1)

Others 10 (2)

O’Shaughnessy et al. [23]

Approximately 65 North America, Europe, and Asia (exact numbers not provided)

Phase II

RCT abiraterone acetate plus 5 mg prednisone, (AA) or AA with 25 mg exemestane (AAE) or 25 mg exemestane only (E) [23]

Post-menopausal women with oestrogen receptor–positive metastatic breast cancer

297; 264 (89)

Missing

24 (8)

7 (2)

Asian 7 (2), Black or African-American 0 (0), others 2 (1)

Senan et al. [24]

125 (21) East Asia, non-East Asia

Phase III

RCT concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed v etoposide-cisplatin and TRT followed by nonpemetrexed doublet consolidation therapy [24]

Patients with stage IIIA/B unresectable non-squamous non-small-cell lung cancer

598; White 421 (70)

Missing 5 (1)

172 (29)

African 27 (5)

East Asian 122 (20)

Others (Hispanic/west Asian, Native American) 23 (4)

Ryan et al. [25]

113 (19) NS

Phase III

RCT doxorubicin plus palifosfamide v doxorubicin plus placebo [25]

Patients with measurable metastatic soft tissue sarcoma

447; White 371 (83)

Unknown 21 (5)

51 (11)

Black 36 (8), Asian 15 (3)

Others (category not identified) 4 (1)

Verma et al. [26]^a)

Welslau et al. [27]^b)

213 (26) NS

Phase III

RCT T-DM1 v lapatinib plus capecitabine [26, 27]

Women with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

991; White 732 (74)

Missing 12 (1)^a)

230 (23)

Asian 180 (18)

Black 50 (5)

Others (not defined) 17 (2)^a)

Escudier et al. [28]

Multi-centre (NS) NS

Phase IIIb

RCT cross-over trial assessing preference for pazopanib v sunitinib [28]

Patients with metastatic renal cell carcinoma

168; White 157 (99)

Missing 9 (5)

Ethnicity Hispanic/Latino 16 (10)

Not Hispanic/Latino 143 (85)

Missing 9 (5)

Race 2 (1)

African-American/African heritage 1 (< 1)

Asian 1 (< 1)

 Beaver et al. [29]

5 centres (1) North West, UK

Others

RCT traditional hospital-based follow-up (HFU) v nurse-led telephone follow-up (TFU) [29]

Women with stage I endometrial cancer

259; White 256 (99)

3 (1) Indian 2 (< 1)

Polish 1 (< 1)

 Horne et al. [30]

Regional unit, (1) (UK)

Others

Evaluation and development of website for patients with stem cell transplant [30]

Adults with allogeneic haematopoietic stem cell transplant

52; White 23 (85)

Missing 29

4 (8) Black British African 3 (11), Black British Caribbean 1 (4) (only Allinex access group data reported n = 27)

 Molassiotis et al. [31]

Centres not stated (1) UK

Others

RCT acupuncture v normal care for managing fatigue [31]

Women with breast cancer

302; White = 283 (94)

Missing 1 (< 1)

18 (6) Black = 4 (1)

Asian/Chinese = 9 (3)

Mixed = 5 (2)

 Molassiotis et al. [32]

14 cancer units, (1) UK

Others

RCT (to clarify if acupressure is effective in managing chemotherapy-related nausea and vomiting) [32]

Patients receiving chemotherapy for cancer

500; Caucasian = 342 (68)

Missing 145 (29)

13 (3) Black = 3 (< 1)

Asian/Chinese = 6 (1)

Mixed = 4 (< 1)

 Neal et al. [33]

3 District General Hospitals (1) North Wales, UK

Others

RCT (comparing self-report or researcher-completed tool measuring duration between first symptoms and cancer diagnosis) [33]

Patients with new primary diagnosis of cancer

201; White British 164 (82)

White 24 (12)

White Irish 1 (< 1)

Other white 9 (4)

Missing 2 (1)

1 (< 1) Indian 1 (< 1)

 Jones et al. [34]

2 NHS trusts and 1 hospice, (1) UK

Exploratory

Patient preference RCT of advance care planning discussions with an independent mediator [34]

Patients attending oncology or hospice

77; White 70 (92)

Missing 1 (1)

2 (3) Black Caribbean 2 (3)

Others 4 (5)